Last week, we provided an overview and analysis of the Federal Court of Canada's review of new amendments to the Patented Medicines Regulations was released. With these regulations serving as the primary tool to regulate the price of pharmaceuticals in Canada, the implications of the new rules—and the Federal Court's decision—are significant.
Those watching the industry are considering what it confirms about changes to Canada's patent regime, what the government's approach to pricing may be going forward in light of the new regulations, and what effect the decision could have on future appeals, including the upcoming appeal still to be heard in Québec.
Watch our intellectual property litigation team in their work-from-home conversation on what the ruling means:
Originally published 07 July, 2020
The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.
